Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 known ✓ | P30926 | 9/20 | 0.65 |
| ▸ | CHRNA3 known ✓ | P32297 | 9/20 | 0.65 |
| ▸ | CHRNA1 known ✓ | P02708 | 2/20 | 0.53 |
| ▸ | CHRNG known ✓ | P07510 | 2/20 | 0.53 |
| ▸ | CHRNB1 known ✓ | P11230 | 2/20 | 0.53 |
| ▸ | CHRND known ✓ | Q07001 | 2/20 | 0.53 |
| ▸ | CHRNA7 known ✓ | P36544 | 3/20 | 0.42 |
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.42 |
| ▸ | HTR3A known ✓ | P46098 | 1/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 15/20 | 0.65 |
| ▸ | CHRNA4 | P43681 | 15/20 | 0.65 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.42 |
| ▸ | CHRNA2 | Q15822 | 1/20 | 0.42 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4406247 | 0.98 | CHRNB2 (0.67) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| Hydrochloric Acid SCHEMBL4689221 | 0.83 | CHRNB2 (0.65) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| Hydrochloric Acid SCHEMBL4687858 | 0.82 | CHRNB2 (0.95) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| SCHEMBL4406133 | 0.81 | CHRNB2 (0.67) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| SCHEMBL3445874 | 0.81 | CHRNB2 (0.41) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| Hydrochloric Acid SCHEMBL4687673 | 0.81 | CHRNB2 (0.50) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| SCHEMBL5685567 | 0.80 | CHRNB2 (0.57) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Hydrochloric Acid SCHEMBL4689642 | 0.80 | CHRNB2 (0.53) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| Hydrochloric Acid SCHEMBL4689234 | 0.80 | CHRNB2 (0.65) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| SCHEMBL4685032 | 0.80 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1044189-B1 | ARYL FUSED AZAPOLYCYCLIC COMPOUNDS | PFIZER PROD INC (US) | 2008-02-13 | — | — | EP | disclosed |
| US-20070275973-A1 | ARYL FUSED AZAPOLYCYCLIC COMPOUNDS | PFIZER INC | 2007-11-29 | — | — | US | disclosed |
| EP-1659114-A2 | PROCESS FOR THE PREPARATION OF BICYCLO[3.2.1]OCTANE FUSED WITH QUINAZOLINE DERIVATIVES | Pfizer Products Inc. (US) | 2006-05-24 | — | — | EP | disclosed |
| US-6951938-B2 | Aryl fused azapolycyclic compounds | PFIZER INC. (US) | 2005-10-04 | — | — | US | disclosed |
| US-6897310-B2 | Aryl fused azapolycyclic compounds | PFIZER INC (US) | 2005-05-24 | — | — | US | disclosed |
| US-6887884-B2 | Aryl fused azapolycyclic compounds | PFIZER INC (US) | 2005-05-03 | — | — | US | disclosed |
| US-20020111350-A1 | Aryl fused azapolycyclic compounds | COE JOTHAM WADSWORTH (US) | 2002-08-15 | — | — | US | disclosed |
| US-6410550-B1 | Aryl fused azapolycyclic compounds | PFIZER INC | 2002-06-25 | — | — | US | disclosed |
| US-20020072524-A1 | Aryl fused azapolycyclic compounds | WADSWORTH JOTHAM (US) | 2002-06-13 | — | — | US | disclosed |
| US-20020072525-A1 | Aryl fused azapolycyclic compounds | PFIZER INC | 2002-06-13 | — | — | US | disclosed |
| EP-1044189-A1 | ARYL FUSED AZAPOLYCYCLIC COMPOUNDS | Pfizer Products Inc. (US) | 2000-10-18 | — | — | EP | disclosed |
| WO-1999035131-A1 | ARYL FUSED AZAPOLYCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 1999-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020072524-A1 | Aryl fused azapolycyclic compounds | GRIN2C, GRIN2A, GRIN2B | CHRNB4 416/4885CHRNA3 183/4885CHRNA1 375/4885 |
| US-20020111350-A1 | Aryl fused azapolycyclic compounds | GRIN2C, GRIN2A, GRIN2B | CHRNB4 416/4885CHRNA3 183/4885CHRNA1 375/4885 |
| US-20070275973-A1 | ARYL FUSED AZAPOLYCYCLIC COMPOUNDS | GRIN2C, GRIN2A, GRIN2B | CHRNB4 284/4885CHRNA3 167/4885CHRNA1 517/4885 |
| US-20020072525-A1 | Aryl fused azapolycyclic compounds | GRIN2C, GRIN2A, GRIN2B | CHRNB4 416/4885CHRNA3 183/4885CHRNA1 375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.